MXPA03006255A - Composiciones farmaceuticas que comprenden peptidos derivados del sistema nervioso central modificados para promover regeneracion de nervios y prevencion de degeracion de nervios. - Google Patents

Composiciones farmaceuticas que comprenden peptidos derivados del sistema nervioso central modificados para promover regeneracion de nervios y prevencion de degeracion de nervios.

Info

Publication number
MXPA03006255A
MXPA03006255A MXPA03006255A MXPA03006255A MXPA03006255A MX PA03006255 A MXPA03006255 A MX PA03006255A MX PA03006255 A MXPA03006255 A MX PA03006255A MX PA03006255 A MXPA03006255 A MX PA03006255A MX PA03006255 A MXPA03006255 A MX PA03006255A
Authority
MX
Mexico
Prior art keywords
prevention
nerve
pharmaceutical compositions
derived peptides
promoting
Prior art date
Application number
MXPA03006255A
Other languages
English (en)
Inventor
Eisenbach-Schwartz Michal
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MXPA03006255A publication Critical patent/MXPA03006255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA03006255A 2001-01-14 2002-01-14 Composiciones farmaceuticas que comprenden peptidos derivados del sistema nervioso central modificados para promover regeneracion de nervios y prevencion de degeracion de nervios. MXPA03006255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14088801A IL140888A0 (en) 2001-01-14 2001-01-14 Pharmaceutical compositions comprising peptides for immune neuroprotection
PCT/IL2002/000032 WO2002055010A2 (en) 2001-01-14 2002-01-14 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration

Publications (1)

Publication Number Publication Date
MXPA03006255A true MXPA03006255A (es) 2003-09-22

Family

ID=11075034

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006255A MXPA03006255A (es) 2001-01-14 2002-01-14 Composiciones farmaceuticas que comprenden peptidos derivados del sistema nervioso central modificados para promover regeneracion de nervios y prevencion de degeracion de nervios.

Country Status (7)

Country Link
US (2) US20040192588A1 (es)
EP (1) EP1572064A4 (es)
JP (1) JP2005504716A (es)
CA (1) CA2434567A1 (es)
IL (1) IL140888A0 (es)
MX (1) MXPA03006255A (es)
WO (1) WO2002055010A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197561A1 (en) * 2004-03-05 2005-09-08 Elsinger Catherine L. System for detecting symptoms, determining staging and gauging drug efficacy in cases of Parkinson's disease
WO2010024927A2 (en) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
CN102186504B (zh) * 2008-09-18 2018-04-06 西塞医疗中心 用于检测阿尔兹海默病的光学方法
US20110124706A1 (en) * 2009-11-25 2011-05-26 Zhigang He SOCS3 Inhibition Promotes CNS Neuron Regeneration
CA2854225A1 (en) 2011-11-01 2013-05-10 Children's Medical Center Corporation Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration
US20150238582A1 (en) * 2012-09-10 2015-08-27 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
CA1341050C (en) * 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US6077509A (en) * 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5633426A (en) * 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5837223A (en) * 1996-08-12 1998-11-17 Revlon Consumer Products Corporation Transfer resistant high lustre cosmetic stick compositions
US6319892B1 (en) * 1997-07-18 2001-11-20 Ralf Gold Use of recombinant myelin protein for treating T-cell-mediated autoimmune diseases of the peripheral nervous system
WO1999034827A1 (en) * 1998-07-21 1999-07-15 Yeda Research And Development Co. Ltd. Activated t-cells and their uses

Also Published As

Publication number Publication date
IL140888A0 (en) 2002-02-10
US20040192588A1 (en) 2004-09-30
EP1572064A2 (en) 2005-09-14
JP2005504716A (ja) 2005-02-17
CA2434567A1 (en) 2002-07-18
WO2002055010A2 (en) 2002-07-18
WO2002055010A3 (en) 2005-07-28
EP1572064A4 (en) 2006-12-06
US20080279869A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
IL160001A0 (en) Peptide based multimeric targeted contrast agents and methods for the preparation thereof
IL160933A0 (en) Methods and compositions for treating ?cap associated diseases
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
HUP0302114A3 (en) Liquis pharmaceutical composition comprising erythropoietin protein, method for its preparation and its use
ZA200202996B (en) Hair treatment compositions comprising particulate substances.
IL197159A0 (en) Rna molecules and pharmaceutical compositions containing the same
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
HU0103078D0 (en) Pharmaceutical compositions and methods for treating cataracts
PL398391A1 (pl) Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania tego koniugatu, jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat hydroksyalkiloskrobi i polipeptydu
IL153359A0 (en) Peptides, compositions and methods for the treatment of burkholderia cepacia
HUP0202781A3 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HK1076261A1 (en) Compositions comprising n-isopropylacrylamide and methods for inhibiting protein adsorbtion on surfaces
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
MXPA03006255A (es) Composiciones farmaceuticas que comprenden peptidos derivados del sistema nervioso central modificados para promover regeneracion de nervios y prevencion de degeracion de nervios.
EP1572064A3 (en) Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
HUP0303469A3 (en) Phtalazinon-derivatives, their use and pharmaceutical compositions containing them
HK1044897A1 (zh) 心絞痛和/或不典型心絞痛的治療方法及其相關藥物組合物和藥劑盒
EP1200078A4 (en) COMPOSITIONS AND METHODS ACTIVATING NERVOUS REGENERATION
AU2002252981A1 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
HUP0402600A3 (en) D-proline derivatives and pharmaceutical compositions containing them
IL156902A0 (en) Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
HK1047407A1 (en) Polymorphs of n-methyl-n-(3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜ-pyrimidin-7-ylÜphenyl)acetamide and compositions and methods related thereto.